Immunotherapy in Breast Cancer

Breast cancer is the most common cancer in women and a multidisciplinary approach has reduced breast cancer mortality. Early stage and locally advanced breast cancers require systemic therapy to reduce recurrence and relapse. Pathologic complete response (pCR) has been one of the main targets of neoadjuvant systemic therapy. With the advent of immune checkpoint inhibitors [...]